| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ... New England Journal of Medicine 362 (5), 402-415, 2010 | 2870 | 2010 |
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis G Giovannoni, G Comi, S Cook, K Rammohan, P Rieckmann, ... New England Journal of Medicine 362 (5), 416-426, 2010 | 1220 | 2010 |
| Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind … G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra, ... The Lancet 374 (9700), 1503-1511, 2009 | 802 | 2009 |
| Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome E Millefiorini, C Gasperini, C Pozzilli, F D’andrea, S Bastianello, ... Journal of neurology 244, 153-159, 1997 | 391 | 1997 |
| Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study B Khatri, F Barkhof, G Comi, HP Hartung, L Kappos, X Montalban, ... The Lancet Neurology, 2011 | 300 | 2011 |
| Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive … F Patti, MP Amato, M Trojano, S Bastianello, MR Tola, B Goretti, L Caniatti, ... Multiple Sclerosis Journal 15 (7), 779-788, 2009 | 275 | 2009 |
| Grey matter loss in relapsing–remitting multiple sclerosis: a voxel-based morphometry study A Prinster, M Quarantelli, G Orefice, R Lanzillo, A Brunetti, C Mollica, ... Neuroimage 29 (3), 859-867, 2006 | 233 | 2006 |
| Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression M Moccia, R Lanzillo, R Palladino, KCM Chang, T Costabile, C Russo, ... Multiple Sclerosis Journal 22 (5), 659-667, 2016 | 170 | 2016 |
| A genome-wide association meta-analysis identifies a novel locus at 17q11. 2 associated with sporadic amyotrophic lateral sclerosis I Fogh, A Ratti, C Gellera, K Lin, C Tiloca, V Moskvina, L Corrado, ... Human molecular genetics 23 (8), 2220-2231, 2014 | 147 | 2014 |
| Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis R Lanzillo, G Cennamo, C Criscuolo, A Carotenuto, N Velotti, F Sparnelli, ... Multiple Sclerosis Journal 24 (13), 1706-1714, 2018 | 129 | 2018 |
| Genetic mapping to 10q23. 3-q24. 2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy M Seri, R Cusano, P Forabosco, R Cinti, F Caroli, P Picco, R Bini, ... The American Journal of Human Genetics 64 (2), 586-593, 1999 | 125 | 1999 |
| Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans G Hayashi, M Jasoliya, S Sahdeo, F Saccà, C Pane, A Filla, A Marsili, ... Human molecular genetics 26 (15), 2864-2873, 2017 | 122 | 2017 |
| Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis F Patti, MP Amato, S Bastianello, L Caniatti, E Di Monte, P Ferrazza, ... Multiple Sclerosis Journal 16 (1), 68-77, 2010 | 121 | 2010 |
| Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks E Portaccio, P Annovazzi, A Ghezzi, M Zaffaroni, L Moiola, V Martinelli, ... Neurology 90 (10), e823-e831, 2018 | 110 | 2018 |
| Epileptic seizures in multiple sclerosis: clinical and EEG correlations P Striano, G Orefice, V Brescia Morra, P Boccella, C Sarappa, R Lanzillo, ... Neurological Sciences 24, 322-328, 2003 | 106 | 2003 |
| Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study E Portaccio, A Bellinvia, M Fonderico, L Pastò, L Razzolini, R Totaro, ... Brain 145 (8), 2796-2805, 2022 | 105 | 2022 |
| Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks E Portaccio, L Moiola, V Martinelli, P Annovazzi, A Ghezzi, M Zaffaroni, ... Neurology 90 (10), e832-e839, 2018 | 105 | 2018 |
| Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies P Iaffaldano, G Lucisano, F Caputo, D Paolicelli, F Patti, M Zaffaroni, ... Therapeutic Advances in Neurological Disorders 14, 17562864211019574, 2021 | 104 | 2021 |
| Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load M Quarantelli, A Ciarmiello, VB Morra, G Orefice, M Larobina, R Lanzillo, ... Neuroimage 18 (2), 360-366, 2003 | 102 | 2003 |
| Natalizumab in the pediatric MS population: results of the Italian registry A Ghezzi, L Moiola, C Pozzilli, V Brescia-Morra, P Gallo, LME Grimaldi, ... BMC neurology 15, 1-6, 2015 | 101 | 2015 |
Saccà FrancescoAssistant Professor of Neurology - University Federico II NaplesGeverifieerd e-mailadres voor unina.it
